It has been recently published that orally administration of HJM-561 PROTAC is effective to diminish EGFR protein levels in patient-derived-xenograft models with EGFR triple mutants, which are common resistant forms of EGFR in patients with advanced NSCLC under Osimertinib treatment [159]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.